TD Asset Management
ARQT icon

TD Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

TD Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-97,200
Closed -$2.82M – 1236
2025
Q4 		$2.82M Buy
+97,200
New +$2.49M ﹤0.01% 909
2022
Q1 		– Sell
-35,920
Closed -$745K – 1485
2021
Q4 		$745K Buy
35,920
+5,410
+18% +$108K ﹤0.01% 1330
2021
Q3 		$729K Hold
30,510
– – ﹤0.01% 1321
2021
Q2 		$712K Sell
30,510
-3,145
-9% -$88.6K ﹤0.01% 1334
2021
Q1 		$974K Buy
33,655
+25,100
+293% +$784K ﹤0.01% 1265
2020
Q4 		$241K Sell
8,555
-11,919
-58% -$292K ﹤0.01% 1410
2020
Q3 		$600K Hold
20,474
– – ﹤0.01% 1198
2020
Q2 		$619K Hold
20,474
– – ﹤0.01% 1172
2020
Q1 		$610K Buy
+20,474
New +$550K ﹤0.01% 1123

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Asset Management's ARQT Position: Q1 2026 in Review

TD Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 97,200 shares — an estimated $2.82M sold.

TD Asset Management first reported a position in ARQT in Q1 2020 and held it in 9 quarters. The position peaked at $2.82M in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • TD Asset Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • TD Asset Management sold 97,200 Arcutis Biotherapeutics shares in Q1 2026, an estimated $2.82M.
  • TD Asset Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 9 quarters.
  • TD Asset Management's Arcutis Biotherapeutics position peaked at $2.82M in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.